Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Presentation TCT 2019

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

Presenter: Andrew Farb

September 28, 2019

Presentation TCT 2019

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

Presenter: Renu Virmani

September 28, 2019

Presentation TCT 2019

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Presenter: Gregg Stone

September 27, 2019

Presentation TCT 2019

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

Presenter: Robert-Jan Van Geuns

September 25, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

Advertisement

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content